Pantech Biosolutions (Liechtenstein) a clinical-stage device company focused on a laser-based transdermal delivery system for large-molecular weight drugs, closed a $19M Series B financing. Participants include StemCell Holding and Gamma Capital Partners.

Ensysce Biosciences (Houston, TX) a development-stage biopharma company focused on carbon nanotube complexes for chemotherapeutic transport, closed a $1.5M Series A financing. Participants include Texas Emerging Technology Fund.

Liquidia Technologies (Research Triangle Park, NC) a development-stage company focused on improving delivery of inhaled therapeutics and vaccines via nanoparticles with optimized characteristics for increased target specificity, closed a $5M Series C financing, bringing the total round to $25M. Participants include Canaan Partners, Pappas Ventures, New Enterprise Associates, Morningside, Firelake Capital and PPD

Liquidia (Morrisville, NC) a development-stage company focused on improving delivery of inhaled therapeutics and vaccines via nanoparticles with optimized characteristics for increased target specificity, closed a $13M Series C financing, bringing the total round to $20M. Participants include Canaan Partners, Pappas Ventures, New Enterprise Associates, Morningside and Firelake Capital.

Carticept (Alpharetta, GA) a near commercial-stage medical device company focused on a computer controlled infusion system for osteoarthritis and cartilage injuries, closed a $20M Series B financing. Participants include SonoSite, Domain Associates and New Enterprise Associates.

Glide Pharma (United Kingdom) a clinical-stage device company focused on the needle-free administration of solid dose therapeutics and vaccines, closed a $4.3M Series D financing. Participants include Hygea VCT and Oxford Technology Management.

MicroCHIPS (Bedford, MA) a development-stage medical device company focused on implantable drug delivery and biosensing for diabetes and osteoporosis, closed a $16.5M Series C financing. Participants include InterWest Partners, Polaris Venture Partners, Novartis Venture Fund, Flybridge Capital Partners, Medtronic, Saints Capital, Intersouth Partners, Care Capital and CSK Venture Capital.

Savara Pharmaceuticals (Austin, TX) a development-stage Dry powder and nebulizer-based drug delivery solution, closed a $1.4M Series A financing. Participants were not identified.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Zogenix (San Diego, CA) a clinical-stage drug:device company focused on a needle-free delivery system of chronic pain therapeutics, closed a $20M Series B financing, bringing the total round to $71M. Participants have included Chicago Growth Partners, Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas McNerney & Partners, Oxford Finance and Abingworth Management.
Note: 2009 Year-in-Review Trend [...]

Quinnova Pharmaceuticals (Newtown, PA) a commercial-stage specialty biopharma company focused on dermatological drug reformulations and foam delivery systems, closed a $17.4M Series B financing. Participants include Safeguard Scientifics, Thomas, McNerney & Partners, H.I.G. Ventures.